{"analyses":[{"ciLowerLimit":"-1.08","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.07","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.291","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.083","paramType":"Mean Difference (Final Values)","paramValue":"-0.51","statisticalMethod":"ANCOVA"},{"ciLowerLimit":"-1.20","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"-0.16","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.264","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.010","paramType":"Mean Difference (Final Values)","paramValue":"-0.68","statisticalMethod":"ANCOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.208","value":"0.29"},{"groupId":"OG001","spread":"0.210","value":"-0.22"},{"groupId":"OG002","spread":"0.167","value":"-0.39"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"144"},{"groupId":"OG001","value":"156"},{"groupId":"OG002","value":"234"}],"units":"Participants"}],"description":"The HADS is a 14-item self-assessment scale that determines the levels of anxiety and depression that a patient is experiencing over the past week. The HADS utilizes a 4-point Likert scale (for example, 0 to 3) for each question and is intended for ages 12 to 65 years. Scores for each domain (anxiety and depression) can range from 0 to 21, with higher scores indicating greater anxiety or depression.\n\nLS mean was calculated using an ANCOVA model which includes geographic region, duration of current episode at baseline (\\<4 years vs. ≥4 years), treatment group and baseline score as fixed factors.","dispersionType":"Standard Error","groups":[{"description":"Participants received two placebo tablets matched to baricitinib, administered orally QD to maintain the blind.","id":"OG000","title":"Placebo"},{"description":"Participants received one 2 mg Baricitinib tablet administered orally QD and one placebo tablet administered orally QD to maintain the blind.","id":"OG001","title":"2 mg Baricitinib"},{"description":"Participants received one 4 mg Baricitinib tablet and one placebo tablet administered orally QD to maintain the blind.","id":"OG002","title":"4 mg Baricitinib"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"All randomized participants with baseline and at least one postbaseline HADS depression score who had evaluable data for this outcome measure. The method used to handle missing data was modified last observation carried forward (mLOCF) which used the most recent nonmissing postbaseline assessment.","reportingStatus":"POSTED","timeFrame":"Baseline,Week 36","title":"Mean Change From Baseline in HADS Depression Score at Week 36","type":"SECONDARY","unitOfMeasure":"score on a scale"}